WEBULL

What You Can Learn From ALT5 Sigma Corporation's (NASDAQ:ALTS) P/S After Its 37% Share Price Crash

Simply Wall St · 10/08/2025 10:17

To the annoyance of some shareholders, ALT5 Sigma Corporation (NASDAQ:ALTS) shares are down a considerable 37% in the last month, which continues a horrid run for the company. Still, a bad month hasn't completely ruined the past year with the stock gaining 64%, which is great even in a bull market.

In spite of the heavy fall in price, ALT5 Sigma's price-to-sales (or "P/S") ratio of 15.6x might still make it look like a strong sell right now compared to other companies in the Pharmaceuticals industry in the United States, where around half of the companies have P/S ratios below 4.8x and even P/S below 1.5x are quite common. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so lofty.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

See our latest analysis for ALT5 Sigma

ps-multiple-vs-industry
NasdaqCM:ALTS Price to Sales Ratio vs Industry October 8th 2025

What Does ALT5 Sigma's Recent Performance Look Like?

Recent times have been advantageous for ALT5 Sigma as its revenues have been rising faster than most other companies. It seems the market expects this form will continue into the future, hence the elevated P/S ratio. If not, then existing shareholders might be a little nervous about the viability of the share price.

Keen to find out how analysts think ALT5 Sigma's future stacks up against the industry? In that case, our free report is a great place to start.

What Are Revenue Growth Metrics Telling Us About The High P/S?

In order to justify its P/S ratio, ALT5 Sigma would need to produce outstanding growth that's well in excess of the industry.

Retrospectively, the last year delivered an explosive gain to the company's top line. Despite this strong recent growth, it's still struggling to catch up as its three-year revenue frustratingly shrank by 2.2% overall. Accordingly, shareholders would have felt downbeat about the medium-term rates of revenue growth.

Looking ahead now, revenue is anticipated to climb by 124% during the coming year according to the sole analyst following the company. With the industry only predicted to deliver 24%, the company is positioned for a stronger revenue result.

In light of this, it's understandable that ALT5 Sigma's P/S sits above the majority of other companies. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.

The Final Word

Even after such a strong price drop, ALT5 Sigma's P/S still exceeds the industry median significantly. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

Our look into ALT5 Sigma shows that its P/S ratio remains high on the merit of its strong future revenues. It appears that shareholders are confident in the company's future revenues, which is propping up the P/S. Unless these conditions change, they will continue to provide strong support to the share price.

There are also other vital risk factors to consider and we've discovered 3 warning signs for ALT5 Sigma (2 are a bit unpleasant!) that you should be aware of before investing here.

It's important to make sure you look for a great company, not just the first idea you come across. So if growing profitability aligns with your idea of a great company, take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E).